Ipsen SA
PAR:IPN

Watchlist Manager
Ipsen SA Logo
Ipsen SA
PAR:IPN
Watchlist
Price: 108.6 EUR -0.46% Market Closed
Market Cap: 9.1B EUR
Have any thoughts about
Ipsen SA?
Write Note

Ipsen SA
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ipsen SA
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Ipsen SA
PAR:IPN
Total Other Income
-€36.2m
CAGR 3-Years
-203%
CAGR 5-Years
-2%
CAGR 10-Years
-13%
Sanofi SA
PAR:SAN
Total Other Income
-€791m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vetoquinol SA
PAR:VETO
Total Other Income
-€249k
CAGR 3-Years
-161%
CAGR 5-Years
2%
CAGR 10-Years
17%
Virbac SA
PAR:VIRP
Total Other Income
-€15.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Total Other Income
-€2.5m
CAGR 3-Years
-26%
CAGR 5-Years
2%
CAGR 10-Years
2%
Medincell SA
PAR:MEDCL
Total Other Income
€9k
CAGR 3-Years
-46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ipsen SA
Glance View

Market Cap
9B EUR
Industry
Pharmaceuticals

Ipsen SA, headquartered in France, is a prominent player in the global biopharmaceutical realm, weaving its story through its commitment to innovation and specialization. Founded in 1929, this family-owned company has evolved significantly, utilizing a diverse mix of scientific research and strategic acquisitions to fuel its growth. Ipsen operates through three principal business segments: Specialty Care, Consumer Healthcare, and Research & Development. Specialty Care, which includes oncology, neuroscience, and rare diseases, is the heart of Ipsen's portfolio, contributing the lion's share of its revenue. The company has honed its focus on developing targeted therapies for complex conditions, leveraging its adeptness in peptide and toxin research. Its success lies in the balance of nurturing homegrown research while acquiring promising biotech firms and novel therapies to expand its offerings and market reach. Beyond its scientific and research prowess, Ipsen's financial robustness stems from a well-orchestrated strategy that intertwines its business operations. The company generates substantial revenue by not only launching innovative products but also through strategic partnerships and licensing agreements that broaden its geographic footprint. Ipsen’s Consumer Healthcare segment complements its operations by delivering over-the-counter products that maintain a steady cash flow, though on a smaller scale compared to Specialty Care. Meanwhile, its Research & Development arm remains the crucible for future growth, as Ipsen invests significantly in pioneering future therapies that align with its core areas of expertise. Through this strategic tapestry, Ipsen has positioned itself as a dynamic entity in the biopharmaceutical industry, consistently striving to deliver value while advancing the frontiers of medicine.

IPN Intrinsic Value
151.09 EUR
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Ipsen SA's Total Other Income?
Total Other Income
-36.2m EUR

Based on the financial report for Jun 30, 2024, Ipsen SA's Total Other Income amounts to -36.2m EUR.

What is Ipsen SA's Total Other Income growth rate?
Total Other Income CAGR 10Y
-13%

Over the last year, the Total Other Income growth was -110%. The average annual Total Other Income growth rates for Ipsen SA have been -203% over the past three years , -2% over the past five years , and -13% over the past ten years .

Back to Top